You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 

CORPORATE

Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 

CORPORATE

Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. EVENTS - 17-10-2016

    Kedrion took part in the 17th ESID Meeting with 44 international guests

    The conference focused on new insights into PIDs’ diagnosis and therapies

    read more 
  2. EVENTS - 23-09-2016

    Pharmaceutical digitization: how to improve patient care and engagement

    Kedrion Biopharma Advisor Prof. Albert Farrugia lectures at "The Future of Science" Conference in Venice, Italy

    read more 
  3. PLASMA & BIOTHERAPIES - 16-09-2016

    Humanitarian Factor IX donation to Afghanistan

    Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries

    read more 
  4. PLASMA & BIOTHERAPIES - 13-09-2016

    Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment

    BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017

    read more 

Pages

For more information please contact: pressoffice@kedrion.com